## Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017.

## (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 y
Hepatitis B <sup>7</sup> (HepB)	1 <sup>st</sup> dose	<b>≺</b> 2 <sup>nd</sup> (	dose>		<b></b>	 	3 <sup>rd</sup> dose		· · · · · · · · · · · · · · · · · · ·								
Rotavirus <sup>2</sup> (RV) RV1 (2-dose series); RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See footnote 2												
Diphtheria, tetanus, & acellular pertussis³ (DTaP: <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		1	<b>≺</b> 4 <sup>th</sup> (	lose>			5 <sup>th</sup> dose					
Haemophilus influenzae type b⁴ (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See footnote 4		<mark>∢3<sup>rd</sup> or 4</mark> See foc	<sup>th</sup> dose,> otnote 4									
Pneumococcal conjugate <sup>s</sup> (PCV13)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		<b>≺</b> 4 <sup>th</sup> (	l dose>									
Inactivated poliovirus <sup>6</sup> (IPV: <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	<b></b>	 	i 3 <sup>rd</sup> dose I	 	>			4 <sup>th</sup> dose					
Influenza <sup>7</sup> (IIV)							i An	i Inual vaccina	ation (IIV) 1 c	or 2 doses				An	nual vaccina 1 dose o	ation (IIV) nly	
Measles, mumps, rubella <sup>®</sup> (MMR)					See foo	otnote 8	<b>≺</b> 1 <sup>st</sup> c	lose>				2 <sup>nd</sup> dose					
Varicella <sup>9</sup> (VAR)							<b>≺</b> 1 <sup>st</sup> c	lose>				2 <sup>nd</sup> dose					
Hepatitis A <sup>10</sup> (HepA)							<mark>&lt;2-c</mark>	dose series, S	See footnote	10>							
Meningococcal <sup>11</sup> (Hib-MenCY ≥6 weeks; MenACWY-D ≥9 mos; MenACWY-CRM ≥2 mos)						See foo	tnote 11	1						1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
Tetanus, diphtheria, & acellular pertussis¹² (Tdap: ≥7 yrs)														Tdap			
Human papillomavirus <sup>13</sup> (HPV)														See footnote 13			
Meningococcal B <sup>11</sup>															See footi	note 11	l
Pneumococcal polysaccharide <sup>5</sup> (PPSV23)													S	ee footnote	5		

NOTE: The above recommendations must be read along with the footnotes of this schedule.